Jon Lundt
Principal at Nexus NeuroTech Ventures
San Francisco, California
Overview
Work Experience
Principal
2023 - Current
Board Member
2024
Board Observer
2024
Cortica provides neurological therapies for children with autism and other developmental differences.
Raised $255,000,000.00 from Morgan Health, Autism Impact Fund and Nexus NeuroTech.
Senior Associate
2022 - 2023
Public (long/short) and private (newco through crossover) investment across medtech, tools, services, AI drug design, diagnostics, and oncology.
Associate
2020 - 2021
Diligence toward investments in CTKB, RXST, TIL, KNTE, Exo, Nodexus, Synthekine, Asher, and New Equilibrium Biosciences.
RA Capital Management is an investment advisor specializing in the life-sciences and drug development sectors.
Board Observer
2021 - 2023
Nodexus is a private research tools company launching a microfluidic cell sorter (the NX One) differentiated by lower cost and higher performance relative to existing instruments in its class.
Nodexus is democratizing access to live single cells for applications including gene editing, drug development, and more.
Raised $30,000,000.00 from Section 32 and RA Capital Management.
Board Observer
2021 - 2023
Exo Imaging is a private AI-enabled medtech company launching a best-in-class handheld point-of-care ultrasound imaging device (Iris) based on novel pMUT semiconductor tech and companion enterprise software (ExoWorks).
Venture Creation Fellow
2019 - 2019
Conceived of first-in-class platform technologies which together formed the basis for company-creation proposals. Due diligence included extensive scientific literature research, interviewing dozens of leading experts, and designing proof-of-concept wet lab experiments. Presented newco proposals to CEO and partnership.
Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Intern
2019 - 2019
Supported deal screening and diligence. Surveyed the landscape of a medtech sector of interest to the firm, documented findings in a report, and presented findings to the partnership. Attended VC University training program co-hosted by the University of California, Berkeley and the National Venture Capital Association.
Mechanical Engineer
2013 - 2014
Contributed to the development of microfluidics-based point-of-care qPCR diagnostic devices for the Bill and Melinda Gates Foundation and Micronics, passive vaccine storage for Intellectual Ventures Laboratory, and autologous cell therapy production equipment for Sotio.
Mechanical Engineer
2010 - 2013
Led hardware R&D efforts toward the production of an assay for the isolation and imaging of rare circulating tumor cells (CTCs – as few as 1 in 50 billion) from whole human blood. Outfitted and oversaw a small machine shop and laser metrology lab. Efforts resulted in 17 patent applications.
RareCyte is a life science research and diagnostic development company focused on characterizing and isolating rare cells in the blood.
Raised $96,000,000.00 from Agilent Technologies, GKCC, Ron Seubert, The Forest Road Company, Arboretum Ventures, F-Prime Capital, HealthQuest Capital, 5AM Ventures and Sheatree Capital.